Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Harats, D.
Right arrow Articles by Shoenfeld, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harats, D.
Right arrow Articles by Shoenfeld, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 1999; 92: 57-59
© 1999 Association of Physicians


Commentary

Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus

D. Harats, J. George1, Y. Levy1, M.A. Khamashta2, G.R.V. Hughes2 and Y. Shoenfeld1

From the Institute of Lipid and Atherosclerosis Research, 1 Department of Medicine `B' and Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, and 2 The Rayne Institute, St. Thomas Hospital, London, UK

Antiphospholipid antibodies (aPL) are found in a variety of autoimmune diseases, and are thought to predispose to arterial and venous thrombosis. These antibodies, when investigated in different assays in vitro, activate endothelial cells and promote uptake of modified LDL to macrophages. These observations suggest that aPL can contribute to atheroma development by targeting some of the sequential steps that constitute early atherogenesis. If substantiated by large-scale clinical trials, the pro-atherogenic properties of aPL may merit screening and intervention programs in selected populations.

Address correspondence to Professor Y. Shoenfeld, Department of Medicine `B', Sheba Medical Center, Tel-Hashomer 52621, Israel. e-mail: shoenfel{at}post.tau.ac.il


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
LupusHome page
D Ben-Ami, E Bar-Meir, and Y Shoenfeld
Stenosis in Antiphospholipid Syndrome: A New Finding with Clinical Implications
Lupus, July 1, 2006; 15(7): 466 - 472.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
J. M. P. de Godoy, M. F. de Godoy, and D. M. Braile
Recurrent Thrombosis in Patients with Deep Vein Thrombosis and/or Venous Thromboembolism Associated with Anticardiolipin Antibodies
Angiology, January 1, 2006; 57(1): 79 - 83.
[Abstract] [PDF]


Home page
LupusHome page
H Koller, P Waldenberger, G Mayer, A R Rosenkranz, and K Lhotta
Letter to the Editor
Lupus, July 1, 2005; 14(7): 566 - 568.
[PDF]


Home page
Rheumatology (Oxford)Home page
S. R. Sangle, D. P. D'Cruz, I. C. Abbs, M. A. Khamashta, and G. R. V. Hughes
Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation
Rheumatology, March 1, 2005; 44(3): 372 - 377.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Rajagopalan, E. C. Somers, R. D. Brook, C. Kehrer, D. Pfenninger, E. Lewis, A. Chakrabarti, B. C. Richardson, E. Shelden, W. J. McCune, et al.
Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity
Blood, May 15, 2004; 103(10): 3677 - 3683.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
S R Sangle and D P D'Cruz
Renal artery stenosis: a new facet of the antiphospholipid (Hughes) syndrome
Lupus, November 1, 2003; 12(11): 803 - 804.
[PDF]


Home page
Ann Rheum DisHome page
S R Sangle, D P D'Cruz, W Jan, M Y Karim, M A Khamashta, I C Abbs, and G R V Hughes
Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension
Ann Rheum Dis, October 1, 2003; 62(10): 999 - 1002.
[Abstract] [Full Text]


Home page
Ann Rheum DisHome page
G Medina, D Casaos, L J Jara, O Vera-Lastra, M Fuentes, L Barile, and M Salas
Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome
Ann Rheum Dis, July 1, 2003; 62(7): 607 - 610.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
S Sangle, D D'Cruz, M Khamashta, M F Tungekar, I Abbs, and G Hughes
Goldblatt's kidney, Hughes syndrome and hypertension
Lupus, November 1, 2002; 11(11): 699 - 703.
[PDF]


Home page
Rheumatology (Oxford)Home page
F. G. I. Jennekens and L. Kater
The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation
Rheumatology, June 1, 2002; 41(6): 619 - 630.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
S Osula, G M Bell, and R S Hornung
Acute myocardial infarction in young adults: causes and management
Postgrad. Med. J., January 1, 2002; 78(915): 27 - 30.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Pratico, R. K. Tangirala, S. Horkko, J. L. Witztum, W. Palinski, and G. A. FitzGerald
Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F2{alpha}-VI levels and the extent of atherosclerosis in ApoE-deficient mice: modulation by vitamin E
Blood, January 15, 2001; 97(2): 459 - 464.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
S E Lane, K Gaffney, R Y Ball, and T J Marshall
Grand Rounds from International Lupus Centres: A swollen leg unmasks longstanding SLE
Lupus, January 1, 2001; 10(1): 4 - 8.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.